[A14AA02, stanozolol, Stanozolol may increase the hypoglycemic activities of Sunitinib.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sunitinib.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Sunitinib.]
[L04AA27, fingolimod, Sunitinib may increase the immunosuppressive activities of Fingolimod.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Sulfadiazine is combined with Sunitinib.]
[J01ED01, sulfadimethoxine, The therapeutic efficacy of Sunitinib can be increased when used in combination with Sulfadimethoxine.]
[A07AB03, sulfaguanidine, The therapeutic efficacy of Sunitinib can be increased when used in combination with Sulfaguanidine.]
[J01ED02, sulfalene, The therapeutic efficacy of Sunitinib can be increased when used in combination with Sulfametopyrazine.]
[J01ED07, sulfamerazine, The therapeutic efficacy of Sunitinib can be increased when used in combination with Sulfamerazine.]
[J01EB03, sulfamethazine, The therapeutic efficacy of Sunitinib can be increased when used in combination with Sulfamethazine.]
[S01AB01, sulfamethizole, The therapeutic efficacy of Sunitinib can be increased when used in combination with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Sunitinib.]
[J01ED05, sulfamethoxypyridazine, The therapeutic efficacy of Sunitinib can be increased when used in combination with Sulfamethoxypyridazine.]
[J01EC03, sulfamoxole, The therapeutic efficacy of Sunitinib can be increased when used in combination with Sulfamoxole.]
[J01EB04, sulfapyridine, The therapeutic efficacy of Sunitinib can be increased when used in combination with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Sunitinib can be increased when combined with Sulfinpyrazone.]
[J01EB01, sulfisomidine, The therapeutic efficacy of Sunitinib can be increased when used in combination with Sulfaisodimidine.]
[S01AB02, sulfisoxazole, The risk or severity of hypoglycemia can be increased when Sulfisoxazole is combined with Sunitinib.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Sulpiride.]
[A10BB04, glibornuride, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Glibornuride.]
[A10BC01, glymidine, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Glymidine.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Sunitinib.]
[L02BA01, tamoxifen, The metabolism of Sunitinib can be increased when combined with Tamoxifen.]
[L01CB02, teniposide, The metabolism of Sunitinib can be decreased when combined with Teniposide.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Sunitinib.]
[G03BA03, testosterone, The metabolism of Sunitinib can be increased when combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Tetracaine.]
[S03AA02, tetracycline, The metabolism of Sunitinib can be decreased when combined with Tetracycline.]
[N05AE05, lurasidone, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Lurasidone.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Sunitinib.]
[N04BC07, apomorphine, The metabolism of Sunitinib can be decreased when combined with Apomorphine.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Sunitinib.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Sunitinib is combined with Eribulin.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Sunitinib is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Sunitinib.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Thiothixene.]
[V04CJ01, thyrotropin, The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Sunitinib.]
[V04CJ02, thyrotropin-releasing hormone, The therapeutic efficacy of Protirelin can be decreased when used in combination with Sunitinib.]
[S01ED01, timolol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Timolol.]
[A10BB05, tolazamide, The risk or severity of hypoglycemia can be increased when Tolazamide is combined with Sunitinib.]
[V04CA01, tolbutamide, The risk or severity of hypoglycemia can be increased when Tolbutamide is combined with Sunitinib.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Sunitinib.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the hypoglycemic activities of Sunitinib.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Sunitinib.]
[L01XF01, tretinoin, The metabolism of Sunitinib can be decreased when combined with Tretinoin.]
[S01BA05, triamcinolone, The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Sunitinib.]
[N05CD05, triazolam, The metabolism of Sunitinib can be decreased when combined with Triazolam.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Trichlormethiazide.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Sunitinib.]
[S01BA09, clobetasone, The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Sunitinib.]
[S01BA10, alclometasone, The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Sunitinib.]
[D07AC02, fluclorolone, The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Sunitinib.]
[R03BA07, mometasone, The risk or severity of hyperglycemia can be increased when Mometasone is combined with Sunitinib.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Sunitinib.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Sunitinib.]
[N06AA06, trimipramine, Trimipramine may decrease the hypoglycemic activities of Sunitinib.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Sunitinib.]
[J01FA08, troleandomycin, The metabolism of Sunitinib can be decreased when combined with Troleandomycin.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Sunitinib.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Sunitinib is combined with Belimumab.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Vandetanib.]
[A10BH05, linagliptin, The metabolism of Sunitinib can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Sunitinib can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Sunitinib can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Sunitinib can be decreased when combined with Rilpivirine.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Sunitinib is combined with Belatacept.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Ezogabine.]
[B01AF01, rivaroxaban, The metabolism of Sunitinib can be decreased when combined with Rivaroxaban.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Indacaterol.]
[B01AC24, ticagrelor, The metabolism of Sunitinib can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Sunitinib can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Sunitinib can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Sunitinib can be increased when combined with Vinblastine.]
[L01CA02, vincristine, The metabolism of Sunitinib can be decreased when combined with Vincristine.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Sunitinib.]
[A11HA03, vitamin E, The metabolism of Sunitinib can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Sunitinib.]
[C03BA10, xipamide, The therapeutic efficacy of Sunitinib can be increased when used in combination with Xipamide.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Sunitinib.]
[N05AF05, zuclopenthixol, The metabolism of Sunitinib can be decreased when combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Sunitinib can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Sunitinib.]
[M05BA03, pamidronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Pamidronic acid.]
[L01FX05, brentuximab vedotin, The metabolism of Sunitinib can be decreased when combined with Brentuximab vedotin.]
[M05BA05, tiludronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Tiludronic acid.]
[L01ED01, crizotinib, The metabolism of Sunitinib can be decreased when combined with Crizotinib.]
[R03DC01, zafirlukast, The metabolism of Sunitinib can be decreased when combined with Zafirlukast.]
[M05BA06, ibandronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Ibandronate.]
[J01MA13, trovafloxacin, The therapeutic efficacy of Sunitinib can be increased when used in combination with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Sunitinib can be decreased when combined with Drospirenone.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sunitinib.]
[N02BA01, aspirin, The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Sunitinib.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Sunitinib is combined with Ruxolitinib.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Sunitinib.]
[C07AB03, atenolol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Atenolol.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Sunitinib.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Sunitinib.]
[J02AC03, voriconazole, The serum concentration of Sunitinib can be increased when it is combined with Voriconazole.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Atropine.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Sunitinib.]
[R07AX02, ivacaftor, The metabolism of Sunitinib can be decreased when combined with Ivacaftor.]
[H02AB11, prednylidene, The risk or severity of hyperglycemia can be increased when Prednylidene is combined with Sunitinib.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Sunitinib.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Sunitinib.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Sunitinib.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Sunitinib.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Sunitinib.]
[M03BX01, baclofen, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Baclofen.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Sunitinib.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sunitinib.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Mirabegron.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Sunitinib is combined with Carfilzomib.]
[V03AX03, cobicistat, The metabolism of Sunitinib can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Sunitinib can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Sunitinib can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Sunitinib can be decreased when combined with Bosutinib.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Sunitinib is combined with Teriflunomide.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Sunitinib is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Sunitinib.]
[N05CA04, barbital, The metabolism of Sunitinib can be increased when combined with Barbital.]
[J05AE04, nelfinavir, The metabolism of Sunitinib can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Sunitinib is combined with Bendamustine.]
[N04BD02, rasagiline, Rasagiline may increase the hypoglycemic activities of Sunitinib.]
[C08CA13, lercanidipine, The metabolism of Sunitinib can be decreased when combined with Lercanidipine.]
[N06DA02, donepezil, Sunitinib may decrease the excretion rate of Donepezil which could result in a higher serum level.]
[N03AX22, perampanel, The metabolism of Sunitinib can be increased when combined with Perampanel.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Sunitinib.]
[H01CB05, pasireotide, The metabolism of Sunitinib can be decreased when combined with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Sunitinib can be decreased when combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Sunitinib.]
[B01AF02, apixaban, The metabolism of Sunitinib can be decreased when combined with Apixaban.]
[C10AX12, lomitapide, The metabolism of Sunitinib can be decreased when combined with Lomitapide.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Bencyclane.]
[A10BH04, alogliptin, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Alogliptin.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Sunitinib can be increased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Sunitinib is combined with Pomalidomide.]
[A10BK02, canagliflozin, Canagliflozin may increase the hypoglycemic activities of Sunitinib.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Sunitinib is combined with Dimethyl fumarate.]
[J01MA15, gemifloxacin, The therapeutic efficacy of Sunitinib can be increased when used in combination with Gemifloxacin.]
[S01AE07, moxifloxacin, The therapeutic efficacy of Sunitinib can be increased when used in combination with Moxifloxacin.]
[A06AX06, tegaserod, Sunitinib may decrease the excretion rate of Tegaserod which could result in a higher serum level.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Sunitinib.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Insulin detemir.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Benzocaine.]
[A10BX05, pramlintide, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Pramlintide.]
[M01AH01, celecoxib, Sunitinib may decrease the excretion rate of Celecoxib which could result in a higher serum level.]
[L04AA18, everolimus, The risk or severity of adverse effects can be increased when Sunitinib is combined with Everolimus.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Sunitinib.]
[L01EC02, dabrafenib, The serum concentration of Sunitinib can be decreased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Benzyl alcohol.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Sunitinib.]
[L01EB03, afatinib, Sunitinib may decrease the excretion rate of Afatinib which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Sunitinib.]
[J05AJ03, dolutegravir, Sunitinib may decrease the excretion rate of Dolutegravir which could result in a higher serum level.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Bepridil.]
[C02KX05, riociguat, Sunitinib may decrease the excretion rate of Riociguat which could result in a higher serum level.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Lixisenatide.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Sunitinib.]
[N06AX26, vortioxetine, The risk or severity of QTc prolongation and torsade de pointes can be increased when Sunitinib is combined with Vortioxetine.]
[G03AC08, etonogestrel, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Etonogestrel.]
[N03AF04, eslicarbazepine, The metabolism of Sunitinib can be increased when combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Sunitinib can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Sunitinib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the hypoglycemic activities of Sunitinib.]
[C07AB04, acebutolol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Acebutolol.]
[N05CH03, tasimelteon, The metabolism of Sunitinib can be decreased when combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Sunitinib can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Sunitinib can be increased when combined with Apremilast.]
[L02BG02, formestane, The metabolism of Sunitinib can be increased when combined with Formestane.]
[S03BA03, betamethasone, The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Sunitinib.]
[S01ED02, betaxolol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Betaxolol.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Albiglutide.]
[L04AC11, siltuximab, The metabolism of Sunitinib can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Sunitinib can be decreased when combined with Ceritinib.]
[B01AC26, vorapaxar, The metabolism of Sunitinib can be decreased when combined with Vorapaxar.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Sunitinib is combined with Vedolizumab.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Sunitinib.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Sunitinib.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Sunitinib is combined with Belinostat.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Sunitinib is combined with Idelalisib.]
[A10BK03, empagliflozin, Empagliflozin may increase the hypoglycemic activities of Sunitinib.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Olodaterol.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Sunitinib is combined with Peginterferon beta-1a.]
[N05CM19, suvorexant, The metabolism of Sunitinib can be decreased when combined with Suvorexant.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Sunitinib.]
[J01XA05, oritavancin, The metabolism of Sunitinib can be increased when combined with Oritavancin.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Dulaglutide.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Decitabine is combined with Sunitinib.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Sunitinib is combined with Pirfenidone.]
[L01EX09, nintedanib, The metabolism of Sunitinib can be decreased when combined with Nintedanib.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Sunitinib is combined with Blinatumomab.]
[L01XK01, olaparib, The metabolism of Sunitinib can be decreased when combined with Olaparib.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation and torsade de pointes can be increased when Sunitinib is combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Sunitinib can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Sunitinib can be decreased when combined with Palbociclib.]
[L01EX08, lenvatinib, Sunitinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Sunitinib is combined with Panobinostat.]
[J05AP07, daclatasvir, The metabolism of Sunitinib can be decreased when combined with Daclatasvir.]
[N02BE01, acetaminophen, The metabolism of Sunitinib can be increased when combined with Acetaminophen.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Sunitinib.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Ivabradine.]
[J05AP06, asunaprevir, The metabolism of Sunitinib can be increased when combined with Asunaprevir.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Brexpiprazole.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Acarbose is combined with Sunitinib.]
[S01EC01, acetazolamide, The metabolism of Sunitinib can be decreased when combined with Acetazolamide.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Insulin degludec.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Sunitinib is combined with Trabectedin.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Sunitinib is combined with Mepolizumab.]
[J02AC05, isavuconazole, The metabolism of Sunitinib can be increased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Sunitinib can be decreased when combined with Osimertinib.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Sunitinib.]
[L01EE02, cobimetinib, The metabolism of Sunitinib can be decreased when combined with Cobimetinib.]
[A10BB31, acetohexamide, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Acetohexamide.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Sunitinib.]
[M04AB05, lesinurad, The metabolism of Sunitinib can be increased when combined with Lesinurad.]
[J05AP10, elbasvir, The metabolism of Sunitinib can be decreased when combined with Elbasvir.]
[N05CA05, aprobarbital, The metabolism of Sunitinib can be increased when combined with Aprobarbital.]
[N02BA02, aloxiprin, Aloxiprin may increase the hypoglycemic activities of Sunitinib.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Sunitinib is combined with Ixekizumab.]
[L01XX52, venetoclax, The metabolism of Sunitinib can be decreased when combined with Venetoclax.]
[N04BC01, bromocriptine, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Bromocriptine.]
[D07AC11, amcinonide, The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Sunitinib.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Sunitinib.]
[N06AA19, amineptin, Amineptine may decrease the hypoglycemic activities of Sunitinib.]
[C08CA01, amlodipine, The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Sunitinib.]
[N05AX17, pimavanserin, The metabolism of Sunitinib can be decreased when combined with Pimavanserin.]
[C03CA02, bumetanide, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Bumetanide.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Bupivacaine.]
[C07AA19, bupranolol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Sunitinib can be decreased when combined with Buprenorphine.]
[L02AE01, buserelin, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Buserelin.]
[N05BE01, buspirone, The metabolism of Sunitinib can be decreased when combined with Buspirone.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Busulfan is combined with Sunitinib.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Sunitinib.]
[P01BE02, artemether, The metabolism of Sunitinib can be decreased when combined with Artemether.]
[J01MA09, sparfloxacin, The therapeutic efficacy of Sunitinib can be increased when used in combination with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Sunitinib.]
[S01GX07, azelastine, The metabolism of Sunitinib can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Sunitinib can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Sunitinib can be decreased when combined with Azithromycin.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Sunitinib is combined with Brodalumab.]
[L01EF02, ribociclib, The metabolism of Sunitinib can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may increase the hypoglycemic activities of Sunitinib.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Sunitinib is combined with Ocrelizumab.]
[N07XX16, deutetrabenazine, The metabolism of Sunitinib can be decreased when combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Sunitinib.]
[C09AA07, benazepril, The risk or severity of hypoglycemia can be increased when Benazepril is combined with Sunitinib.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Benfluorex.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Oxybuprocaine.]
[D05AX03, calcitriol, The metabolism of Sunitinib can be increased when combined with Calcitriol.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Sunitinib.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Sunitinib.]
[J05AE09, tipranavir, The metabolism of Sunitinib can be decreased when combined with Tipranavir.]
[H03BA03, benzylthiouracil, The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Sunitinib.]
[N07XX13, valbenazine, The metabolism of Sunitinib can be decreased when combined with Valbenazine.]
[L04AB02, infliximab, The metabolism of Sunitinib can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Sunitinib can be decreased when combined with Midostaurin.]
[H05AA04, abaloparatide, The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Sunitinib.]
[L01ED04, brigatinib, Sunitinib may decrease the excretion rate of Brigatinib which could result in a higher serum level.]
[N04BD03, safinamide, Safinamide may increase the hypoglycemic activities of Sunitinib.]
[L04AC14, sarilumab, The metabolism of Sunitinib can be increased when combined with Sarilumab.]
[J01MA23, delafloxacin, The therapeutic efficacy of Sunitinib can be increased when used in combination with Delafloxacin.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Sunitinib is combined with Guselkumab.]
[D01AC10, bifonazole, The metabolism of Sunitinib can be decreased when combined with Bifonazole.]
[L01BC06, capecitabine, The risk or severity of QTc prolongation can be increased when Capecitabine is combined with Sunitinib.]
[L01XX59, enasidenib, The metabolism of Sunitinib can be increased when combined with Enasidenib.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Sunitinib is combined with Vorinostat.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Sunitinib.]
[L01EF03, abemaciclib, Sunitinib may decrease the excretion rate of Abemaciclib which could result in a higher serum level.]
[C07AB07, bisoprolol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Sunitinib can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Bopindolol.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Sunitinib.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Sunitinib.]
[R03BA02, budesonide, The risk or severity of hyperglycemia can be increased when Budesonide is combined with Sunitinib.]
[L01EL02, acalabrutinib, The metabolism of Sunitinib can be decreased when combined with Acalabrutinib.]
[J05AX18, letermovir, The metabolism of Sunitinib can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, Butriptyline may decrease the hypoglycemic activities of Sunitinib.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Acetyldigoxin.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Semaglutide.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Sunitinib can be increased when used in combination with Ertugliflozin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Acrivastine.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Macimorelin.]
[L02BB05, apalutamide, The metabolism of Sunitinib can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Sunitinib can be increased when combined with Carbamazepine.]
[H03BB01, carbimazole, The therapeutic efficacy of Carbimazole can be decreased when used in combination with Sunitinib.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Carbinoxamine.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Sunitinib.]
[C07AG02, carvedilol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Carvedilol.]
[B02BX09, fostamatinib, The metabolism of Sunitinib can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The metabolism of Sunitinib can be decreased when combined with Cannabidiol.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Sunitinib is combined with Baricitinib.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Encorafenib.]
[C07AB08, celiprolol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Celiprolol.]
[L01XX62, ivosidenib, The metabolism of Sunitinib can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Sunitinib can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, Sunitinib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level.]
[J05AX24, tecovirimat, The metabolism of Sunitinib can be increased when combined with Tecovirimat.]
[J05AG06, doravirine, The metabolism of Sunitinib can be decreased when combined with Doravirine.]
[L01EM04, duvelisib, The metabolism of Sunitinib can be decreased when combined with Duvelisib.]
[L01EB07, dacomitinib, The metabolism of Sunitinib can be decreased when combined with Dacomitinib.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Sunitinib.]
[A10BB06, carbutamide, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Carbutamide.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Chloroprocaine.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Inotersen.]
[L01XK04, talazoparib, Sunitinib may decrease the excretion rate of Talazoparib which could result in a higher serum level.]
[R03BB08, revefenacin, Sunitinib may decrease the excretion rate of Revefenacin which could result in a higher serum level.]
[L01ED05, lorlatinib, The metabolism of Sunitinib can be increased when combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Sunitinib can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Sunitinib.]
[L01EX13, gilteritinib, The metabolism of Sunitinib can be decreased when combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Amifampridine.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Sunitinib is combined with Ravulizumab.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Sunitinib.]
[C01BG07, cifenline, The risk or severity of hypoglycemia can be increased when Cibenzoline is combined with Sunitinib.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Sunitinib.]
[P02BX04, triclabendazole, The metabolism of Sunitinib can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Sunitinib can be increased when combined with Esketamine.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Sunitinib is combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Sunitinib can be decreased when combined with Clarithromycin.]
[N05BA09, clobazam, The metabolism of Sunitinib can be increased when combined with Clobazam.]
[D07AB21, clocortolone, The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Sunitinib.]
[H02AB14, cloprednol, The risk or severity of hyperglycemia can be increased when Cloprednol is combined with Sunitinib.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Sunitinib.]
[L04AB01, etanercept, The metabolism of Sunitinib can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The risk or severity of hyperglycemia can be increased when Cortivazol is combined with Sunitinib.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Sunitinib is combined with Risankizumab.]
[L01EM03, alpelisib, The serum concentration of Alpelisib can be increased when it is combined with Sunitinib.]
[L02BB06, darolutamide, Sunitinib may decrease the excretion rate of Darolutamide which could result in a higher serum level.]
[L01EX15, pexidartinib, Sunitinib may increase the hepatotoxic activities of Pexidartinib.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Cicletanine.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Sunitinib is combined with Upadacitinib.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Sunitinib can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Sunitinib can be decreased when combined with Pretomanid.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Sunitinib.]
[N04CX01, istradefylline, The metabolism of Sunitinib can be decreased when combined with Istradefylline.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Cyclothiazide.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Insulin pork.]
[J01DB01, cephalexin, The metabolism of Sunitinib can be decreased when combined with Cephalexin.]
[J01DB09, cephradine, The metabolism of Sunitinib can be increased when combined with Cefradine.]
[H02AB13, deflazacort, The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Sunitinib.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Sunitinib.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Sunitinib.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Sunitinib is combined with Diroximel fumarate.]
[G03AC09, desogestrel, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Desogestrel.]
[B06AX03, voxelotor, The serum concentration of Sunitinib can be increased when it is combined with Voxelotor.]
[N03AX25, cenobamate, The serum concentration of Sunitinib can be decreased when it is combined with Cenobamate.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Sunitinib.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Sunitinib.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Dexchlorpheniramine.]
[N05CM21, lemborexant, The metabolism of Sunitinib can be decreased when combined with Lemborexant.]
[L01XX72, tazemetostat, The metabolism of Sunitinib can be decreased when combined with Tazemetostat.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Sunitinib is combined with Teprotumumab.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Sunitinib.]
[J05AB16, remdesivir, The metabolism of Sunitinib can be decreased when combined with Remdesivir.]
[S01AE06, gatifloxacin, The therapeutic efficacy of Sunitinib can be increased when used in combination with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Sunitinib can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Sunitinib can be decreased when combined with Amprenavir.]
[G04CB02, dutasteride, The metabolism of Sunitinib can be decreased when combined with Dutasteride.]
[L04AA38, ozanimod, Sunitinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01EE04, selumetinib, The metabolism of Sunitinib can be decreased when combined with Selumetinib.]
[G03DB08, dienogest, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Dienogest.]
[D07AC19, difluprednate, The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Sunitinib.]
[M01AH02, rofecoxib, The metabolism of Sunitinib can be increased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Sunitinib can be increased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Sunitinib can be increased when combined with Clevidipine.]
[C01BD07, dronedarone, The serum concentration of Sunitinib can be increased when it is combined with Dronedarone.]
[J01FA13, dirithromycin, The metabolism of Sunitinib can be decreased when combined with Dirithromycin.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Sunitinib.]
[S03AA08, chloramphenicol, The metabolism of Sunitinib can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Chlorcyclizine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Sunitinib.]
[D07XB03, fluprednidene, The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Sunitinib.]
[L01EX19, ripretinib, Sunitinib may decrease the excretion rate of Ripretinib which could result in a higher serum level.]
[S01BA14, loteprednol, The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Sunitinib.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Sunitinib is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Sunitinib is combined with Stepronin.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Sunitinib.]
[R06AX22, ebastine, The metabolism of Sunitinib can be decreased when combined with Ebastine.]
[J05AX29, fostemsavir, Sunitinib may decrease the excretion rate of Fostemsavir which could result in a higher serum level.]
[L04AC19, satralizumab, The serum concentration of Sunitinib can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The metabolism of Sunitinib can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Sunitinib can be increased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Chlorothiazide.]
[R06AB04, chlorpheniramine, The metabolism of Sunitinib can be decreased when combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Sunitinib can be increased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The risk or severity of hypoglycemia can be increased when Chlorpropamide is combined with Sunitinib.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Sunitinib.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Chlorthalidone.]
[N02BA03, choline salicylate, Choline salicylate may increase the hypoglycemic activities of Sunitinib.]
[N06BX18, vinpocetine, The risk or severity of hypoglycemia can be increased when Vinpocetine is combined with Sunitinib.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Sunitinib.]
[A16AX20, lonafarnib, The metabolism of Sunitinib can be decreased when combined with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Fludarabine is combined with Sunitinib.]
[L02BX04, relugolix, The metabolism of Sunitinib can be decreased when combined with Relugolix.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Sunitinib is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Sunitinib can be increased when it is combined with Abametapir.]
[V03AF12, trilaciclib, Sunitinib may decrease the excretion rate of Trilaciclib which could result in a higher serum level.]
[N03AX10, felbamate, The metabolism of Sunitinib can be increased when combined with Felbamate.]
[G04CB01, finasteride, The metabolism of Sunitinib can be decreased when combined with Finasteride.]
[J01MB07, flumequine, The therapeutic efficacy of Sunitinib can be increased when used in combination with Flumequine.]
[R03BA03, flunisolide, The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Sunitinib.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Sunitinib.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Insulin human.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Sunitinib.]
[S01LA08, bevacizumab, The risk or severity of adverse effects can be increased when Sunitinib is combined with Bevacizumab.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Sunitinib.]
[G03GA06, follitropin beta, The therapeutic efficacy of Follitropin can be decreased when used in combination with Sunitinib.]
[A02BA01, cimetidine, The metabolism of Sunitinib can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, The risk or severity of hypoglycemia can be increased when Cinnarizine is combined with Sunitinib.]
[J01MB06, cinoxacin, The therapeutic efficacy of Sunitinib can be increased when used in combination with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Sunitinib can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Sunitinib can be decreased when combined with Infigratinib.]
[S03AA07, ciprofloxacin, The metabolism of Sunitinib can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Sunitinib.]
[N06AB04, citalopram, The metabolism of Sunitinib can be decreased when combined with Citalopram.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Sunitinib is combined with Pegcetacoplan.]
[H01AC07, somapacitan, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Somapacitan.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Sunitinib.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Sunitinib is combined with Belumosudil.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Sunitinib is combined with Fexinidazole.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Sunitinib is combined with Anifrolumab.]
[L01XX74, belzutifan, The serum concentration of Sunitinib can be decreased when it is combined with Belzutifan.]
[H01AC09, lonapegsomatropin, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Lonapegsomatropin.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Mobocertinib.]
[L04AA59, avacopan, The metabolism of Sunitinib can be decreased when combined with Avacopan.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Clemastine.]
[A10BB12, glimepiride, The risk or severity of hypoglycemia can be increased when Glimepiride is combined with Sunitinib.]
[A10BB08, gliquidone, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Gliquidone.]
[J01FF01, clindamycin, The metabolism of Sunitinib can be decreased when combined with Clindamycin.]
[N06AX25, St. John's wort extract, The metabolism of Sunitinib can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Sunitinib can be increased when it is combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Sunitinib is combined with Ropeginterferon alfa-2b.]
[D07AD01, clobetasol, The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Sunitinib.]
[J04BA01, clofazimine, The metabolism of Sunitinib can be decreased when combined with Clofazimine.]
[C10AB01, clofibrate, The metabolism of Sunitinib can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Sunitinib can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Sunitinib can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, Clomipramine may decrease the hypoglycemic activities of Sunitinib.]
[S01EA04, clonidine, The metabolism of Sunitinib can be decreased when combined with Clonidine.]
[C01EB24, mavacamten, The serum concentration of Sunitinib can be decreased when it is combined with Mavacamten.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Tirzepatide.]
[C03BA03, clopamide, The therapeutic efficacy of Sunitinib can be increased when used in combination with Clopamide.]
[A02BC08, vonoprazan, The metabolism of Sunitinib can be decreased when combined with Vonoprazan.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Sunitinib is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Sunitinib is combined with Deucravacitinib.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation and torsade de pointes can be increased when Sunitinib is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation and torsade de pointes can be increased when Sunitinib is combined with Granisetron.]
[J05AX31, lenacapavir, The metabolism of Sunitinib can be decreased when combined with Lenacapavir.]
[N05AH02, clozapine, The metabolism of Sunitinib can be increased when combined with Clozapine.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Sotagliflozin.]
[D07AC12, halometasone, The risk or severity of hyperglycemia can be increased when Halometasone is combined with Sunitinib.]
[H01AC08, somatrogon, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Cocaine.]
[L04AC21, bimekizumab, The metabolism of Sunitinib can be increased when combined with Bimekizumab.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Sunitinib.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Sunitinib is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Sunitinib.]
[A04AA03, tropisetron, The risk or severity of QTc prolongation and torsade de pointes can be increased when Sunitinib is combined with Tropisetron.]
[A10BX03, nateglinide, The metabolism of Sunitinib can be decreased when combined with Nateglinide.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Mecasermin.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Sunitinib is combined with Nelarabine.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Insulin glargine.]
[J01FA15, telithromycin, The metabolism of Sunitinib can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Sunitinib.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Desloratadine.]
[H01AX01, pegvisomant, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sunitinib.]
[J02AC02, itraconazole, The metabolism of Sunitinib can be decreased when combined with Itraconazole.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Emedastine.]
[N05BA10, ketazolam, The metabolism of Sunitinib can be decreased when combined with Ketazolam.]
[L01EA01, imatinib, The serum concentration of Sunitinib can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Sunitinib can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Lacidipine.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sunitinib.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Sunitinib.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Sunitinib.]
[S01BA03, cortisone, The risk or severity of hyperglycemia can be increased when Cortisone is combined with Sunitinib.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Lofexidine.]
[S01AE04, lomefloxacin, The therapeutic efficacy of Sunitinib can be increased when used in combination with Lomefloxacin.]
[C08CA11, manidipine, The metabolism of Sunitinib can be decreased when combined with Manidipine.]
[S01BA08, medrysone, The risk or severity of hyperglycemia can be increased when Medrysone is combined with Sunitinib.]
[C07AA14, mepindolol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Mepindolol.]
[H02AB15, meprednisone, The risk or severity of hyperglycemia can be increased when Meprednisone is combined with Sunitinib.]
[R06AD07, mequitazine, The metabolism of Sunitinib can be decreased when combined with Mequitazine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Adenosine.]
[C04AX01, cyclandelate, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Sunitinib.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Sunitinib.]
[C03DA04, eplerenone, The metabolism of Sunitinib can be decreased when combined with Eplerenone.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Melperone.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Sunitinib.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Cyclopenthiazide.]
[J01FA03, midecamycin, The metabolism of Sunitinib can be decreased when combined with Midecamycin.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Miglitol is combined with Sunitinib.]
[L01AA01, cyclophosphamide, The metabolism of Sunitinib can be increased when combined with Cyclophosphamide.]
[N06AX07, minaprine, Minaprine may increase the hypoglycemic activities of Sunitinib.]
[S01XA18, cyclosporine, Sunitinib may increase the immunosuppressive activities of Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the hypoglycemic activities of Sunitinib.]
[N06BA07, modafinil, The metabolism of Sunitinib can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Sunitinib.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Sunitinib.]
[C10AA07, rosuvastatin, The metabolism of Sunitinib can be decreased when combined with Rosuvastatin.]
[C03XA02, conivaptan, The metabolism of Sunitinib can be decreased when combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Sunitinib.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Sunitinib.]
[M01AH05, etoricoxib, The metabolism of Sunitinib can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Sunitinib.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Sunitinib.]
[G03XA01, danazol, The metabolism of Sunitinib can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Sunitinib can be decreased when combined with Dapsone.]
[L01DB02, daunorubicin, The metabolism of Sunitinib can be decreased when combined with Daunorubicin.]
[C07AB12, nebivolol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Nebivolol.]
[N06AX06, nefazodone, The metabolism of Sunitinib can be decreased when combined with Nefazodone.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sunitinib.]
[N06AB10, escitalopram, The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Sunitinib.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Solifenacin.]
[A07EC03, olsalazine, Olsalazine may increase the hypoglycemic activities of Sunitinib.]
[N06AA01, desipramine, The metabolism of Sunitinib can be decreased when combined with Desipramine.]
[S01BA11, desonide, The risk or severity of hyperglycemia can be increased when Desonide is combined with Sunitinib.]
[D07XC02, desoximetasone, The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Sunitinib.]
[H02AA03, desoxycorticosterone, The risk or severity of hyperglycemia can be increased when Desoxycortone is combined with Sunitinib.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Sunitinib.]
[N03AF02, oxcarbazepine, The metabolism of Sunitinib can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Sunitinib.]
[G04BD04, oxybutynin, The metabolism of Sunitinib can be decreased when combined with Oxybutynin.]
[L04AB04, adalimumab, The metabolism of Sunitinib can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Sunitinib can be decreased when combined with Gefitinib.]
[R05DA09, dextromethorphan, The metabolism of Sunitinib can be decreased when combined with Dextromethorphan.]
[H05AA02, teriparatide, The therapeutic efficacy of Teriparatide can be decreased when used in combination with Sunitinib.]
[N06AB05, paroxetine, The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Sunitinib.]
[B01AC04, clopidogrel, The metabolism of Sunitinib can be decreased when combined with Clopidogrel.]
[N05BA01, diazepam, The metabolism of Sunitinib can be decreased when combined with Diazepam.]
[V03AH01, diazoxide, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Diazoxide.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Phenol.]
[N06AA08, dibenzepin, Dibenzepin may decrease the hypoglycemic activities of Sunitinib.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Cinchocaine.]
[M05BA02, clodronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Clodronic acid.]
[S01EC02, dichlorphenamide, The therapeutic efficacy of Sunitinib can be increased when used in combination with Diclofenamide.]
[J01CF01, dicloxacillin, The metabolism of Sunitinib can be increased when combined with Dicloxacillin.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Sunitinib.]
[A07AB02, phthalylsulfathiazole, The therapeutic efficacy of Sunitinib can be increased when used in combination with Phthalylsulfathiazole.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Pinaverium.]
[A10BG03, pioglitazone, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Sunitinib.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Sunitinib is combined with Ixabepilone.]
[L01EB02, erlotinib, The metabolism of Sunitinib can be decreased when combined with Erlotinib.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Sunitinib is combined with Pirarubicin.]
[C03CA03, piretanide, The therapeutic efficacy of Sunitinib can be increased when used in combination with Piretanide.]
[L02AA01, diethylstilbestrol, The metabolism of Sunitinib can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Sunitinib can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Sunitinib.]
[N02BA11, diflunisal, Diflunisal may increase the hypoglycemic activities of Sunitinib.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Digitoxin.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Sunitinib.]
[C10AX09, ezetimibe, Sunitinib may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Sunitinib.]
[C04AE04, dihydroergocristine, The metabolism of Sunitinib can be decreased when combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The metabolism of Sunitinib can be decreased when combined with Dihydroergotamine.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Sunitinib.]
[J05AE08, atazanavir, The metabolism of Sunitinib can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Sunitinib.]
[H03BC01, potassium perchlorate, The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Sunitinib.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Pramocaine.]
[D07AC18, prednicarbate, The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Sunitinib.]
[C08DB01, diltiazem, The metabolism of Sunitinib can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Dimenhydrinate.]
[M02AX03, dimethyl sulfoxide, The metabolism of Sunitinib can be decreased when combined with Dimethyl sulfoxide.]
[C05CA03, diosmin, The metabolism of Sunitinib can be decreased when combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Diphenhydramine.]
[N06AA23, quinupramine, Quinupramine may decrease the hypoglycemic activities of Sunitinib.]
[A03FA02, cisapride, The metabolism of Sunitinib can be decreased when combined with Cisapride.]
[S01XA23, sirolimus, The metabolism of Sunitinib can be decreased when combined with Sirolimus.]
[C01BA03, disopyramide, The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Sunitinib.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Sunitinib is combined with Natalizumab.]
[P03AA04, disulfiram, The metabolism of Sunitinib can be decreased when combined with Disulfiram.]
[S02AA12, rifamycin SV, The metabolism of Sunitinib can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Sunitinib can be increased when combined with Rifapentine.]
[N07XX02, riluzole, Sunitinib may decrease the excretion rate of Riluzole which could result in a higher serum level.]
[N05AX08, risperidone, The metabolism of Sunitinib can be decreased when combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Levocetirizine.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Sunitinib.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Ropivacaine.]
[J01MB01, rosoxacin, The therapeutic efficacy of Sunitinib can be increased when used in combination with Rosoxacin.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Sunitinib is combined with Antilymphocyte immunoglobulin (horse).]
[S01AA13, fusidic acid, The metabolism of Sunitinib can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The therapeutic efficacy of Sunitinib can be increased when used in combination with Pipemidic acid.]
[S02BA08, fluocinolone acetonide, The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Sunitinib.]
[A04AD12, aprepitant, The metabolism of Sunitinib can be decreased when combined with Aprepitant.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Bortezomib is combined with Sunitinib.]
[J05AE07, fosamprenavir, The metabolism of Sunitinib can be decreased when combined with Fosamprenavir.]
[G04BE08, tadalafil, The metabolism of Sunitinib can be decreased when combined with Tadalafil.]
[C02KX02, ambrisentan, The metabolism of Sunitinib can be decreased when combined with Ambrisentan.]
[C01EB18, ranolazine, The metabolism of Sunitinib can be decreased when combined with Ranolazine.]
[R03AC12, salmeterol, The metabolism of Sunitinib can be decreased when combined with Salmeterol.]
[H05BA01, salmon calcitonin, The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Sunitinib.]
[A03FA03, domperidone, The metabolism of Sunitinib can be decreased when combined with Domperidone.]
[N06AA16, dothiepin, Dosulepin may decrease the hypoglycemic activities of Sunitinib.]
[N06AA12, doxepin, Doxepin may decrease the hypoglycemic activities of Sunitinib.]
[L01DB01, doxorubicin, The metabolism of Sunitinib can be decreased when combined with Doxorubicin.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Sunitinib.]
[N06AB06, sertraline, The risk or severity of hypoglycemia can be increased when Sertraline is combined with Sunitinib.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Sunitinib.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Droperidol.]
[C10AA01, simvastatin, The metabolism of Sunitinib can be decreased when combined with Simvastatin.]
[A07AB04, succinylsulfathiazole, The therapeutic efficacy of Sunitinib can be increased when used in combination with Succinylsulfathiazole.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Sultopride.]
[N02CC01, sumatriptan, Sunitinib may decrease the excretion rate of Sumatriptan which could result in a higher serum level.]
[C07AB13, talinolol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Talinolol.]
[H01AA01, corticotropin, The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Sunitinib.]
[J01MA05, temafloxacin, The therapeutic efficacy of Sunitinib can be increased when used in combination with Temafloxacin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Sunitinib.]
[D01BA02, terbinafine, The metabolism of Sunitinib can be increased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Terodiline.]
[C07AA16, tertatolol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Tertatolol.]
[N06AX14, tianeptine, Tianeptine may decrease the hypoglycemic activities of Sunitinib.]
[N06AG03, toloxatone, Toloxatone may increase the hypoglycemic activities of Sunitinib.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Sunitinib.]
[N03AX11, topiramate, The metabolism of Sunitinib can be increased when combined with Topiramate.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Toremifene.]
[C03CA04, torsemide, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Torasemide.]
[H02CA01, trilostane, The risk or severity of hyperglycemia can be increased when Trilostane is combined with Sunitinib.]
[G03GA05, follitropin alfa, The therapeutic efficacy of Follitropin can be decreased when used in combination with Sunitinib.]
[L02AE04, triptorelin, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Triptorelin.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Sunitinib is combined with Trofosfamide.]
[J01MA04, enoxacin, The therapeutic efficacy of Sunitinib can be increased when used in combination with Enoxacin.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Sunitinib.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Sunitinib.]
[N06AX16, venlafaxine, The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Sunitinib.]
[S01GA03, xylometazoline, The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Sunitinib.]
[C08CA12, mepirodipine, The metabolism of Sunitinib can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Sunitinib can be decreased when combined with Epinephrine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Sunitinib.]
[N03AX15, zonisamide, The metabolism of Sunitinib can be decreased when combined with Zonisamide.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Insulin glulisine.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Sunitinib.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Sunitinib.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Sunitinib.]
[N02CA02, ergotamine, The metabolism of Sunitinib can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The metabolism of Sunitinib can be decreased when combined with Erythromycin.]
[G03CA03, estradiol, The metabolism of Sunitinib can be decreased when combined with Estradiol.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Estramustine is combined with Sunitinib.]
[G03CA57, estrogens, conjugated (USP), Sunitinib may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.]
[J04AK02, ethambutol, The metabolism of Sunitinib can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Sunitinib.]
[R03BA05, fluticasone, The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Sunitinib.]
[C10AA04, fluvastatin, The metabolism of Sunitinib can be decreased when combined with Fluvastatin.]
[D07AC21, halobetasol, The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Sunitinib.]
[L02AA03, ethinyl estradiol, The metabolism of Sunitinib can be decreased when combined with Ethinylestradiol.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Ibutilide.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Sunitinib.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Etidocaine.]
[L01CB01, etoposide, The metabolism of Sunitinib can be decreased when combined with Etoposide.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Ajmaline.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Sunitinib.]
[J01MA08, fleroxacin, The therapeutic efficacy of Sunitinib can be increased when used in combination with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Sunitinib can be decreased when combined with Astemizole.]
[R06AX12, terfenadine, The metabolism of Sunitinib can be decreased when combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Sunitinib can be decreased when combined with Fluvoxamine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Sunitinib.]
[L02AE02, leuprolide, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Leuprolide.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Sunitinib.]
[C10AA03, pravastatin, Sunitinib may decrease the excretion rate of Pravastatin which could result in a higher serum level.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sunitinib.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Sunitinib.]
[P02CA03, albendazole, The metabolism of Sunitinib can be decreased when combined with Albendazole.]
[C08CA02, felodipine, The metabolism of Sunitinib can be decreased when combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of hypoglycemia can be increased when Fendiline is combined with Sunitinib.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Sunitinib.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Sunitinib.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Sunitinib.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Sunitinib.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Flecainide.]
[J01CF05, floxacillin, The metabolism of Sunitinib can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of QTc prolongation can be increased when Flucytosine is combined with Sunitinib.]
[H02AA02, fludrocortisone, The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Sunitinib.]
[D07XB01, flumethasone, The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Sunitinib.]
[N07CA03, flunarizine, The risk or severity of hypoglycemia can be increased when Flunarizine is combined with Sunitinib.]
[D07AC08, fluocinonide, The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Sunitinib.]
[N06AA14, melitracen, Melitracen may decrease the hypoglycemic activities of Sunitinib.]
[H02AB03, fluocortolone, The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Sunitinib.]
[V03AZ01, ethanol, The metabolism of Sunitinib can be increased when combined with Ethanol.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Sunitinib.]
[S01CB05, fluorometholone, The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Sunitinib.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Sunitinib.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Sunitinib.]
[G03BA01, fluoxymesterone, Fluoxymesterone may increase the hypoglycemic activities of Sunitinib.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Flupentixol.]
[D07AC07, flurandrenolide, The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Sunitinib.]
[N05AG01, fluspirilene, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Sunitinib.]
[L02BB01, flutamide, The metabolism of Sunitinib can be decreased when combined with Flutamide.]
[V04CX02, folic acid, Sunitinib may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[L01BC03, tegafur, The risk or severity of QTc prolongation can be increased when Tegafur is combined with Sunitinib.]
[G01AX06, furazolidone, Furazolidone may increase the hypoglycemic activities of Sunitinib.]
[J05AE10, darunavir, The serum concentration of Sunitinib can be increased when it is combined with Darunavir.]
[C03CA01, furosemide, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Furosemide.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Sunitinib.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Sunitinib.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Gallopamil.]
[N03AA04, barbexaclone, The metabolism of Sunitinib can be increased when combined with Barbexaclone.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Degarelix.]
[L01EA02, dasatinib, The metabolism of Sunitinib can be decreased when combined with Dasatinib.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Liraglutide.]
[J05AG04, etravirine, The metabolism of Sunitinib can be increased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Methsuximide.]
[N01AH02, alfentanil, The metabolism of Sunitinib can be decreased when combined with Alfentanil.]
[L01EH01, lapatinib, The metabolism of Sunitinib can be decreased when combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Sunitinib can be decreased when combined with Glyburide.]
[A10BB09, gliclazide, The risk or severity of hypoglycemia can be increased when Gliclazide is combined with Sunitinib.]
[A10BB07, glipizide, The risk or severity of hypoglycemia can be increased when Glipizide is combined with Sunitinib.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Dofetilide.]
[C02CA04, doxazosin, The metabolism of Sunitinib can be decreased when combined with Doxazosin.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Sunitinib.]
[L01EX02, sorafenib, The metabolism of Sunitinib can be decreased when combined with Sorafenib.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Sunitinib.]
[D01BA01, griseofulvin, The metabolism of Sunitinib can be increased when combined with Griseofulvin.]
[L02AE03, goserelin, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Goserelin.]
[P01BX01, halofantrine, The metabolism of Sunitinib can be decreased when combined with Halofantrine.]
[D07AD02, halcinonide, The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Sunitinib.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Haloperidol.]
[L02AE05, histrelin, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Histrelin.]
[N05AH04, quetiapine, The metabolism of Sunitinib can be decreased when combined with Quetiapine.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Insulin aspart.]
[L01CE02, irinotecan, The metabolism of Sunitinib can be decreased when combined with Irinotecan.]
[M04AA01, allopurinol, Sunitinib may decrease the excretion rate of Allopurinol which could result in a higher serum level.]
[C09CA01, losartan, The metabolism of Sunitinib can be decreased when combined with Losartan.]
[G03DC01, allylestrenol, The metabolism of Sunitinib can be decreased when combined with Allylestrenol.]
[A07EC02, mesalamine, Mesalazine may increase the hypoglycemic activities of Sunitinib.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Sunitinib.]
[J05AG01, nevirapine, The metabolism of Sunitinib can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Sunitinib can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypoglycemia can be increased when Nimesulide is combined with Sunitinib.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Oxatomide.]
[C02DB02, hydralazine, The metabolism of Sunitinib can be decreased when combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Sunitinib.]
[D07AC16, hydrocortisone aceponate, The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Sunitinib.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Hydroflumethiazide.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Sunitinib can be increased when used in combination with Hydroxychloroquine.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Sunitinib.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Sunitinib can be increased when combined with Rifabutin.]
[S01BA13, rimexolone, The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Sunitinib.]
[M05BA07, risedronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Risedronic acid.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Idarubicin is combined with Sunitinib.]
[L01AA06, ifosfamide, The metabolism of Sunitinib can be increased when combined with Ifosfamide.]
[H01AC02, somatrem, Somatrem may decrease the hypoglycemic activities of Sunitinib.]
[N06AA02, imipramine, The metabolism of Sunitinib can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The metabolism of Sunitinib can be increased when combined with Paclitaxel.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Terlipressin.]
[R01AD07, tixocortol, The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Sunitinib.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Sunitinib.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Topotecan is combined with Sunitinib.]
[C03BA11, indapamide, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Indapamide.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Sunitinib.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Sunitinib.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Sunitinib.]
[N06AX17, milnacipran, The metabolism of Sunitinib can be decreased when combined with Milnacipran.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Eculizumab is combined with Sunitinib.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Articaine.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Sitagliptin is combined with Sunitinib.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Sunitinib.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Sunitinib.]
[A10BH02, vildagliptin, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Vildagliptin.]
[C10AA06, cerivastatin, The metabolism of Sunitinib can be increased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Anagrelide.]
[C07AA01, alprenolol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Alprenolol.]
[C03BA02, quinethazone, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Quinethazone.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sunitinib.]
[N06AA13, iprindole, Iprindole may decrease the hypoglycemic activities of Sunitinib.]
[N06AF05, iproniazid, Iproniazid may increase the hypoglycemic activities of Sunitinib.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypoglycemic activities of Sunitinib.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Sunitinib.]
[J04AC01, isoniazid, The metabolism of Sunitinib can be decreased when combined with Isoniazid.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Exenatide.]
[P02CF01, ivermectin, Sunitinib may decrease the excretion rate of Ivermectin which could result in a higher serum level.]
[H01AC01, somatropin, Somatotropin may decrease the hypoglycemic activities of Sunitinib.]
[L04AC07, tocilizumab, The metabolism of Sunitinib can be increased when combined with Tocilizumab.]
[J02AB02, ketoconazole, The metabolism of Sunitinib can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Olanzapine.]
[V03AC03, deferasirox, The metabolism of Sunitinib can be increased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Sunitinib can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Mizolastine.]
[A16AX01, thioctic acid, The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Sunitinib.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Sunitinib can be increased when used in combination with Nalidixic acid.]
[C07AG01, labetalol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Labetalol.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Sunitinib.]
[N03AX18, lacosamide, The metabolism of Sunitinib can be decreased when combined with Lacosamide.]
[C03CC01, ethacrynic acid, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Etacrynic acid.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Sunitinib.]
[G03AD01, levonorgestrel, The metabolism of Sunitinib can be decreased when combined with Levonorgestrel.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Lidoflazine.]
[N06BA13, armodafinil, The metabolism of Sunitinib can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Sunitinib.]
[N06AA07, lofepramine, Lofepramine may decrease the hypoglycemic activities of Sunitinib.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Lomustine is combined with Sunitinib.]
[A07DA03, loperamide, The risk or severity of hypoglycemia can be increased when Loperamide is combined with Sunitinib.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Sunitinib.]
[L01EG01, temsirolimus, The metabolism of Sunitinib can be decreased when combined with Temsirolimus.]
[V04CC02, magnesium sulfate, The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Sunitinib.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Sunitinib is combined with Pralatrexate.]
[L01EA03, nilotinib, The metabolism of Sunitinib can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Sunitinib.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Sunitinib.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Sunitinib.]
[C03BA05, mefruside, The therapeutic efficacy of Sunitinib can be increased when used in combination with Mefruside.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Melphalan is combined with Sunitinib.]
[N02AB02, meperidine, The metabolism of Sunitinib can be decreased when combined with Meperidine.]
[N03AA01, mephobarbital, The metabolism of Sunitinib can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Mepivacaine.]
[L02BG01, aminoglutethimide, The metabolism of Sunitinib can be increased when combined with Aminoglutethimide.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Mesoridazine.]
[G03BB01, mesterolone, Mesterolone may increase the hypoglycemic activities of Sunitinib.]
[N05AX13, paliperidone, The metabolism of Sunitinib can be decreased when combined with Paliperidone.]
[A10BA02, metformin, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Metformin.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation and torsade de pointes can be increased when Sunitinib is combined with Dolasetron.]
[H01CB03, lanreotide, The metabolism of Sunitinib can be decreased when combined with Lanreotide.]
[N07BC02, methadone, The metabolism of Sunitinib can be decreased when combined with Methadone.]
[J05AF05, lamivudine, Sunitinib may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[S01EC05, methazolamide, The therapeutic efficacy of Sunitinib can be increased when used in combination with Methazolamide.]
[H03BB02, methimazole, The metabolism of Sunitinib can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Sunitinib.]
[N02BG08, ziconotide, The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Sunitinib.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Sunitinib.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Methotrimeprazine.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Methyclothiazide.]
[V04CG05, methylene blue, The metabolism of Sunitinib can be decreased when combined with Methylene blue.]
[G02AB01, methylergonovine, The metabolism of Sunitinib can be decreased when combined with Methylergometrine.]
[H02AB04, methylprednisolone, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Sunitinib.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Sunitinib.]
[N03AF03, rufinamide, The metabolism of Sunitinib can be increased when combined with Rufinamide.]
[G03EK01, methyltestosterone, Methyltestosterone may increase the hypoglycemic activities of Sunitinib.]
[N02CA04, methysergide, The metabolism of Sunitinib can be decreased when combined with Methysergide.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Sunitinib.]
[C03BA08, metolazone, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Metolazone.]
[C07AB02, metoprolol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Metoprolol.]
[P01AB01, metronidazole, The metabolism of Sunitinib can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The metabolism of Sunitinib can be increased when combined with Metyrapone.]
[S02AA13, miconazole, The metabolism of Sunitinib can be decreased when combined with Miconazole.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Sunitinib.]
[G03XB01, mifepristone, The metabolism of Sunitinib can be increased when combined with Mifepristone.]
[J01FA11, miocamycin, The metabolism of Sunitinib can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Sunitinib can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Sunitinib.]
[L03AC01, aldesleukin, The metabolism of Sunitinib can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, The metabolism of Sunitinib can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Sunitinib can be decreased when combined with Amitriptyline.]
[A04AA05, palonosetron, The risk or severity of QTc prolongation and torsade de pointes can be increased when Sunitinib is combined with Palonosetron.]
[L04AB05, certolizumab pegol, The metabolism of Sunitinib can be increased when combined with Certolizumab pegol.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Sunitinib is combined with Ofatumumab.]
[L01EX03, pazopanib, The metabolism of Sunitinib can be decreased when combined with Pazopanib.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Sunitinib.]
[N05CA02, amobarbital, The metabolism of Sunitinib can be increased when combined with Amobarbital.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Sunitinib.]
[G03XC01, raloxifene, The metabolism of Sunitinib can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, Amoxapine may decrease the hypoglycemic activities of Sunitinib.]
[N03AB05, fosphenytoin, The metabolism of Sunitinib can be increased when combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sunitinib.]
[C07AA12, nadolol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Nadolol.]
[J01CF06, nafcillin, The metabolism of Sunitinib can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The metabolism of Sunitinib can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Sunitinib can be increased when combined with Anakinra.]
[S01XA11, nandrolone, Nandrolone phenpropionate may increase the hypoglycemic activities of Sunitinib.]
[A10BG01, troglitazone, The metabolism of Sunitinib can be increased when combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Sunitinib.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Sunitinib.]
[L01CD02, docetaxel, The metabolism of Sunitinib can be decreased when combined with Docetaxel.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Sunitinib.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Levosimendan.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Sunitinib.]
[N06AX23, desvenlafaxine, The metabolism of Sunitinib can be decreased when combined with Desvenlafaxine.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Sunitinib.]
[C10AD02, niacin, The metabolism of Sunitinib can be decreased when combined with Niacin.]
[N06AF02, nialamide, Nialamide may increase the hypoglycemic activities of Sunitinib.]
[C08CA04, nicardipine, The metabolism of Sunitinib can be decreased when combined with Nicardipine.]
[C08CA05, nifedipine, The metabolism of Sunitinib can be decreased when combined with Nifedipine.]
[C08CA06, nimodipine, The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Sunitinib.]
[C08CA07, nisoldipine, The metabolism of Sunitinib can be decreased when combined with Nisoldipine.]
[C08CA08, nitrendipine, The metabolism of Sunitinib can be decreased when combined with Nitrendipine.]
[J01XE01, nitrofurantoin, Sunitinib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The metabolism of Sunitinib can be decreased when combined with Zaleplon.]
[G03DC02, norethindrone, The metabolism of Sunitinib can be decreased when combined with Norethisterone.]
[S01AE02, norfloxacin, The therapeutic efficacy of Sunitinib can be increased when used in combination with Norfloxacin.]
[C02KX01, bosentan, The metabolism of Sunitinib can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, Nortriptyline may decrease the hypoglycemic activities of Sunitinib.]
[R05DA07, noscapine, The metabolism of Sunitinib can be decreased when combined with Noscapine.]
[G02CA02, nylidrin, The risk or severity of hypoglycemia can be increased when Nylidrin is combined with Sunitinib.]
[H01CB02, octreotide, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Octreotide.]
[S02AA16, ofloxacin, The therapeutic efficacy of Sunitinib can be increased when used in combination with Ofloxacin.]
[J01FA05, oleandomycin, The metabolism of Sunitinib can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Sunitinib can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Sunitinib can be increased when combined with Omeprazole.]
[N06AA05, opipramol, Opipramol may decrease the hypoglycemic activities of Sunitinib.]
[G04CA02, tamsulosin, The therapeutic efficacy of Sunitinib can be increased when used in combination with Tamsulosin.]
[M05BA08, zoledronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Zoledronic acid.]
[A14AA08, oxandrolone, Oxandrolone may increase the hypoglycemic activities of Sunitinib.]
[J01MB05, oxolinic acid, The therapeutic efficacy of Sunitinib can be increased when used in combination with Oxolinic acid.]
[C07AA02, oxprenolol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Oxprenolol.]
[N02AA05, oxycodone, The metabolism of Sunitinib can be decreased when combined with Oxycodone.]
[A14AA05, oxymetholone, Oxymetholone may increase the hypoglycemic activities of Sunitinib.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sunitinib.]
[J04AA01, aminosalicylic acid, Aminosalicylic acid may increase the hypoglycemic activities of Sunitinib.]
[N05AH05, asenapine, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Asenapine.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Papaverine.]
[H02AB05, paramethasone, The risk or severity of hyperglycemia can be increased when Paramethasone is combined with Sunitinib.]
[C02KC01, pargyline, Pargyline may increase the hypoglycemic activities of Sunitinib.]
[J01MA03, pefloxacin, The therapeutic efficacy of Sunitinib can be increased when used in combination with Pefloxacin.]
[C07AA23, penbutolol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of hypoglycemia can be increased when Penfluridol is combined with Sunitinib.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Sunitinib.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Sunitinib.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Sunitinib.]
[N05CA01, pentobarbital, The metabolism of Sunitinib can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Sunitinib.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Sunitinib.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Sunitinib.]
[N06AF03, phenelzine, Phenelzine may increase the hypoglycemic activities of Sunitinib.]
[A10BA01, phenformin, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Phenformin.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Pheniramine.]
[N03AA02, phenobarbital, The metabolism of Sunitinib can be increased when combined with Phenobarbital.]
[A08AA01, phentermine, The therapeutic efficacy of Sunitinib can be increased when used in combination with Phentermine.]
[M02AA01, phenylbutazone, The metabolism of Sunitinib can be increased when combined with Phenylbutazone.]
[N03AB02, phenytoin, The metabolism of Sunitinib can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Sunitinib can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The therapeutic efficacy of Sunitinib can be increased when used in combination with Levofloxacin.]
[L02BB03, bicalutamide, The metabolism of Sunitinib can be decreased when combined with Bicalutamide.]
[C08CX01, mibefradil, The metabolism of Sunitinib can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Sunitinib can be decreased when combined with Pimozide.]
[C07AA03, pindolol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Sunitinib.]
[J05AE01, saquinavir, The metabolism of Sunitinib can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Piperazine.]
[N05AC04, pipothiazine, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Pipotiazine.]
[J01MA11, grepafloxacin, The therapeutic efficacy of Sunitinib can be increased when used in combination with Grepafloxacin.]
[J05AG02, delavirdine, The metabolism of Sunitinib can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Sunitinib can be decreased when combined with Irbesartan.]
[A10BG02, rosiglitazone, The risk or severity of hypoglycemia can be increased when Rosiglitazone is combined with Sunitinib.]
[A03AE01, alosetron, The risk or severity of QTc prolongation and torsade de pointes can be increased when Sunitinib is combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Sunitinib can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Sunitinib can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Sunitinib can be decreased when combined with Saxagliptin.]
[V03AB21, potassium iodide, The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Sunitinib.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Insulin lispro.]
[C10AA08, pitavastatin, Sunitinib may decrease the excretion rate of Pitavastatin which could result in a higher serum level.]
[C07AB01, practolol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Prajmaline.]
[P02BA01, praziquantel, The metabolism of Sunitinib can be decreased when combined with Praziquantel.]
[C02CA01, prazosin, Sunitinib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[S03BA02, prednisolone, The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Sunitinib.]
[H02AB07, prednisone, The risk or severity of hyperglycemia can be increased when Prednisone is combined with Sunitinib.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of hypoglycemia can be increased when Prenylamine is combined with Sunitinib.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Sunitinib can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Sunitinib can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Sunitinib can be increased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Procainamide.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Sunitinib.]
[C10AB05, fenofibrate, The metabolism of Sunitinib can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Prochlorperazine.]
[G03DA04, progesterone, The metabolism of Sunitinib can be decreased when combined with Progesterone.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Promazine.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Promethazine is combined with Sunitinib.]
[C01BC03, propafenone, The therapeutic efficacy of Sunitinib can be increased when used in combination with Propafenone.]
[L01XH02, romidepsin, The metabolism of Sunitinib can be decreased when combined with Romidepsin.]
[N01AX10, propofol, The metabolism of Sunitinib can be decreased when combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Sunitinib can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, The therapeutic efficacy of Sunitinib can be increased when used in combination with Propranolol.]
[H03BA02, propylthiouracil, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Sunitinib.]
[N06AA11, protriptyline, Protriptyline may decrease the hypoglycemic activities of Sunitinib.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Sunitinib.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Sunitinib.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Mepyramine.]
[P01AX05, quinacrine, The metabolism of Sunitinib can be decreased when combined with Quinacrine.]
[C01BA01, quinidine, The metabolism of Sunitinib can be decreased when combined with Quinidine.]
[P01BC01, quinine, The metabolism of Sunitinib can be increased when combined with Quinine.]
[D07AC10, diflorasone, The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Sunitinib.]
[C02AA02, reserpine, The metabolism of Sunitinib can be increased when combined with Reserpine.]
[J04AB02, rifampin, The metabolism of Sunitinib can be increased when combined with Rifampicin.]
[J01FA06, roxithromycin, The metabolism of Sunitinib can be decreased when combined with Roxithromycin.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Sunitinib.]
[S01BC08, salicylic acid, Salicylic acid may increase the hypoglycemic activities of Sunitinib.]
[N05CA06, secobarbital, The metabolism of Sunitinib can be increased when combined with Secobarbital.]
[N04BD01, selegiline, Selegiline may increase the hypoglycemic activities of Sunitinib.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Sunitinib is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Sunitinib.]
[H01CB01, somatostatin, The metabolism of Sunitinib can be decreased when combined with Somatostatin.]
[C07AA07, sotalol, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Sunitinib.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Sunitinib.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Sunitinib.]
[N03AG01, valproic acid, The metabolism of Sunitinib can be decreased when combined with Valproic acid.]
[M05BA01, etidronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Etidronic acid.]
[M05BA04, alendronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Alendronic acid.]
[D07AB02, hydrocortisone butyrate, The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Sunitinib.]
[D07AB11, hydrocortisone probutate, The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Sunitinib.]
[H02CA04, levoketoconazole, The metabolism of Sunitinib can be decreased when combined with Levoketoconazole.]
